Inhibikase Therapeutics, Inc.
Small-molecule c-Abl kinase inhibitor therapeutics for alpha-synucleinopathies (multiple system atrophy and Parkinson's disease)
- Sector
- Biotech
- Headquarters
- Atlanta, GA
- Latest Form D
- $8M offered, Jun 2024
- Total capital
- $28M
- Federal grants
- $16.7M
- 15 awards · 2015–2021
- Rank in peer group#209 of 514
- Private capital raised
- $4.2M
- 2 Form D · last Jun 2024
- 29 months since last filing
- Federal contracts
- $7.1M
- 1 award · Defense
- Rank in Biotech#68 of 4373
- Granted patents
- 8
- 12 pending · first 2017
- Rank in peer group#40 of 514
Capital timeline
Latest events
- Offering registeredForm D · SEC · 2nd filing$8M
- Private capital raisedForm D · SEC · 1st filing$4.2M
- Federal grantHealth and Human S · Phase I · Kinase activation in multiple system atrophy$386K
- Federal grantHealth and Human S · Phase II · Advanced therapeutic for Parkinson's Disease$1.5M
- Federal grantHealth and Human S · Phase II · Advanced therapeutic for Parkinson's Disease$1.6M
- Federal grantHealth and Human S · Phase II · Advanced Prodrug Treatment for CML$986K
- Federal grantHealth and Human S · Phase II · Advanced Prodrug Treatment for CML$1M
Show 11 earlier federal awards
- Federal grantHealth and Human S · Phase II · Advanced Prodrug Treatment for CML$2M
- Federal grantHealth and Human S · Phase II · Advanced therapeutic for Parkinson's Disease$1.6M
- Federal grantHealth and Human S · Phase II · Advanced PML antiviral$1M
- Federal grantHealth and Human S · Phase I · Prodrug treatment for CML$285K
- Federal grantHealth and Human S · Phase I · Prodrug treatment for CML$285K
- Federal grantHealth and Human S · Phase II · Advanced therapeutic for Parkinson's Disease$1.6M
- Federal grantHealth and Human S · Phase II · Advanced PML antiviral$2M
- Federal grantHealth and Human S · Phase II · Advanced PML antiviral$1M
- Federal grantHealth and Human S · Phase II · Novel DFG out inhibitors of Abl-kinases to treat PML$788K
- Federal grantHealth and Human S · Phase II · Novel DFG out inhibitors of Abl-kinases to treat PML$753K
- Federal contractDefense · Multi-pathogen Antiviral Medical Countermeasure Deploying Fda Approved Drug$7.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
125months
from Inhibikase Therapeutics, Inc.’s first federal award to its first private round.
- First federal award · Aug 2012
- Defense · $7.1M
- First Form D · Feb 2023
- $4.2M · 1st Form D
- Awards before first raise
- 16 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#209 · top 41%
- Granted patents#40 · top 8%
- Linked publications#54 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Milton H. WernerResearcherExecutive Officer, DirectorLinked by 8 patents · $15.4M in grants as PI
- Dennis H. BermanDirectorNamed in SEC Form D filings
- Garth H. Lees-RolfeExecutive OfficerNamed in SEC Form D filings
- Gisele DionDirectorNamed in SEC Form D filings
- Joseph Frattaroli, C.P.A.Executive OfficerNamed in SEC Form D filings
- Milton H. Werner Ph.DExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
- Paul H. GrintDirectorNamed in SEC Form D filings
- Paul Grint, M.D.DirectorNamed in SEC Form D filings
- Roy H. FreemanDirectorNamed in SEC Form D filings
- Roy Freeman M.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 20- PendingCompositions And Methods For Treating Pulmonary Arterial HypertensionUSPTOApplication 19542047
- GrantedCompositions And Methods For Inhibiting KinasesUSPTOUS 12,629,371
- PendingCompositions And Methods For Inhibiting KinasesUSPTOApplication 18894338
Show all 20 patent records
- Compositions And Methods For Treating Pulmonary Arterial HypertensionJun 25, 2026 · Application 19542047Pending
- Compositions And Methods For Inhibiting KinasesMay 19, 2026 · US 12,629,371Granted
- Compositions And Methods For Inhibiting KinasesAug 7, 2025 · Application 18894338Pending
- Compositions And Methods For Inhibiting KinasesAug 15, 2023 · US 11,725,005Granted
- Compositions And Methods For Inhibiting KinasesAug 9, 2022 · US 11,407,747Granted
- Compositions And Methods For Inhibiting KinasesFeb 2, 2021 · US 10,906,896Granted
- Compositions And Methods For Inhibiting KinasesJul 9, 2019 · US 10,344,027Granted
- Compositions And Methods For Inhibiting KinasesJun 11, 2019 · US 10,316,031Granted
- Compositions And Methods For Inhibiting KinasesNov 6, 2018 · US 10,118,923Granted
- Compositions And Methods For Inhibiting KinasesNov 28, 2017 · US 9,828,370Granted
- Compositions And Methods For Inhibiting KinasesApplication PCTUS2025018865Pending
- Compositions And Methods For Treating Pulmonary Arterial HypertensionApplication PCTUS2025022429Pending
- Compositions And Methods For Inhibiting KinasesApplication PCTUS2017058263Pending
- Compositions And Methods For Inhibiting KinasesApplication PCTUS2016028914Pending
- Methods For Treating Hcv InfectionApplication PCTUS2014036877Pending
- Compositions And Methods For Inhibiting KinasesApplication 18433883Pending
- Methods For Prevention And Treatment Of InfluenzaApplication PCTUS2011059590Pending
- Compositions And Methods For Inhibiting KinasesApplication 18210348Pending
- Compositions And Methods For Inhibiting KinasesApplication 63562837Pending
- Compositions And Methods For Treating Pulmonary Arterial HypertensionApplication 63573253Pending
Recent research by its founders
- Time-to-Event Analyses of UPDRS and MDS-UPDRS Motor Examination and Functional Outcomes in Early Parkinson’s Disease Clinical Trials20260 cites
- A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease20247 cites
- The 201 Trial in Untreated Parkinson’s Disease (P9-3.011)20240 cites
Related companies, and why
- BNB PLUS CORP.Similar federal contract value in Biotech · $8M in contracts
- DISCOVERX CORPSimilar federal contract value in Biotech · $7.6M in contracts
- PROSCI, INC.Similar federal contract value in Biotech · $7.5M in contracts
- DYNAVAX TECHNOLOGIES CORPORATIONSimilar federal contract value in Biotech · $7.1M in contracts
- MEDIGEN, INC.Similar federal contract value in Biotech · $7M in contracts
- REJUVENATE BIO INCSimilar federal contract value in Biotech · $6.3M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .